Skip to main content
BioSyent Inc. logo

BioSyent Inc. — Investor Relations & Filings

Ticker · RX ISIN · CA0906901081 TSXV Manufacturing
Open in API
Filings indexed 410 across all filing types
Latest filing 2026-05-15 Notice of Dividend Amou…
Country CA Canada
Listing TSXV RX

About BioSyent Inc.

https://www.biosyent.com/

BioSyent Inc. is a profitable, growth-oriented specialty pharmaceutical company focused on enhancing patient lives by addressing unmet medical needs. The company's primary business model involves sourcing, in-licensing, and acquiring innovative pharmaceutical and healthcare products globally for development and commercialization. BioSyent markets a diverse portfolio of products, including prescription, over-the-counter, and behind-the-counter options, primarily serving markets in Canada and select international regions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Notice of Dividend Amount Classification · 95% confidence The document is a press release announcing the board’s declaration of a quarterly dividend, specifying the dividend amount, payment date, and record date. This matches the definition of a Notice of Dividend Amount (Code: DIV).
2026-05-15 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 85% confidence The document is a Form 52-109FV2, titled “Certification of Interim Filings,” containing only the CEO’s certification statements and disclaimers. It does not include any actual interim financial statements or MD&A content—it simply attests to their review and fair presentation. Under the certification rule, an officer’s attestation or certification letter—despite referencing an interim period—should be classified as a regulatory filing, not as the interim report itself.
2026-05-15 English
Interim MD&A - English.pdf
Management Reports Classification · 90% confidence The document is titled “Management’s Discussion and Analysis” for the three months ended March 31, 2026 and 2025. It contains management’s detailed explanation of the company’s operations, performance metrics, outlook, accounting policies, strategy, and non-IFRS measures, but does not include the actual financial statements themselves. This fits the definition of a Management Report (MDA).
2026-05-15 English
News release - English.pdf
Interim / Quarterly Report Classification · 87% confidence The document is a press release announcing BioSyent’s first quarter 2026 financial results. It goes beyond high-level highlights by including the Interim Unaudited Condensed Consolidated Statements of Comprehensive Income and Statements of Financial Position, along with substantive financial tables and reconciliation of non-IFRS measures. It thus meets the criteria for an Interim/Quarterly Report (period shorter than a fiscal year with actual financial statements), rather than a simple Earnings Release (key highlights only). Q1 2026
2026-05-15 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 97% confidence The document is titled “Interim Unaudited Condensed Consolidated Financial Statements” for the three months ended March 31, 2026 and 2025, contains full interim financial statements (balance sheet, income statement, cash flows, equity changes) and accompanying notes, and is prepared under IAS 34 for a fiscal quarter. This matches the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-15 English
News release - English.pdf
Regulatory Filings
2026-05-08 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.